Reshaping the HIV treatment and prevention landscape
Robust capital allocation framework
Priorities aligned on growth drivers, improving productivity, enhancing Rol
Research & Development
(including BD)
SG&A
(Commercial excellence, customer/patient facing)
Capital Expenditure
(Sustainability and productivity)
Dividends
Continued investment in innovation and productivity
Value creating bolt on acquisitions and strategic
collaborations to strengthen the pipeline:
-
-
4 core TAs and other large-scale opportunities,
R&D strategy aligned
First-in-Class or Best-in-Class potential
- Evaluate non-organic vs organic opportunities
-
Discipline on NPV and IRR criteria
Product launches, data & analytics, competitive intelligence,
customer and patient insights
£1-1.5bn capital projects, focus on technology platforms,
supply chain network, sustainability
Progressive dividend policy
40%-60% EPS pay-out ratio
gsk
108View entire presentation